Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage

Neurosurgery

Volumn 59, Issue 5, 2006, Pages 1102-1107

  Atalay, Basar ^a,b   Caner, Hakan ^a   Cekinmez, Melih ^a   Ozen, Ozlem ^a   Celasun, Bulent ^a   Altinors, Nur ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Apoptosis; Nitric oxide; Phosphodiesterase V inhibitor; Sildenafil citrate; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CONTROLLED STUDY; DRUG EFFECT; IMAGE ANALYSIS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RABBIT; STUDENT T TEST; SUBARACHNOID HEMORRHAGE; VASCULAR ENDOTHELIUM;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; BASILAR ARTERY; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RABBITS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 33845188745     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000245605.22817.44     Document Type: Article

References (38)

1. Alksne JF, Branson PJ: Prevention of experimental subarachnoid hemorrhage-induced intracranial arterial vasonecrosis with phosphodiesterase inhibitor phthalazinol (EG-626). Stroke 10:638-644, 1979.
2. Aoki K, Zubkov AY, Ross IB, Zhang JH: Therapeutic effect of caspase inhibitors in the prevention of apoptosis and reversal of chronic cerebral vasospasm. J Clin Neurosci 9:672-677, 2002.
3. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S: Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Report of seven cases. Neurosurgery 48:723-730, 2001.
4. Baumhaekel M, Scheffler P, Boehm M: Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 69:178-179, 2005.
5. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748, 1995.
6. Beavo JA, Conti M, Heaslip RJ: Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405, 1994.
7. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC: Sildenafil citrate (Viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 57:22-27, 2005.
8. Caner H, Kwan Al, Arthur A, Jeng AY, Lappe RW, Kassell NF, Lee KS: Systemic administration of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J Neurosurg 85:917-922, 1996.
9. Caner HH, Kwan AL, Bavbek M, Kilinc K, Durieux M, Lee K, Kassell NF: Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. Acta Neurochir (Wien) 142:455-461, 2000.
10. Clatterbuck RE, Gailloud P, Tierney T, Clatterbuck VM, Murphy KJ, Tamargo RJ: Controlled release of a nitric oxide donor for the prevention of delayed cerebral vasospasm following experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 103:745-751, 2005.
11. Flamm ES, Kim J, Lin J, Ransohoff J: Phosphodiesterase inhibitors and cerebral vasospasm. Arch Neurol 32:569-571, 1975.
12. Frazier JL, Pradilla G, Wang PP, Tamargo RJ: Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. J Neurosurg 101:93-98, 2004.
13. Gabikian P, Clatterbuck RE, Eberhart CG, Tyler BM, Tierney TS, Tamargo RJ: Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: Toxicity and efficacy studies in rabbits and rats. Stroke 33:2681-2686, 2002.
14. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40:1232-1240, 2002.
15. Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M: Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol Res 24:607-612, 2002.
16. Juliana AE, Abbad FC: Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: Successful treatment with sildenafil. Eur J Pediatr 164:626-629, 2005.
17. Khajavi K, Ayzman I, Shearer D, Jones SC, Levy JH, Prayson RA, Skibinski CI, Hahn JF, Chyatte D: Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 40:354-363, 1997.
18. Li J, Fu P, Deleon M, French BA, French SW: The effect of Viagra (sildenafil citrate) on liver injury caused by chronic ethanol intragastric feeding in rats. Exp Mol Pathol 78:101-108, 2005.
19. Machado RF, Martyr S, Kato GJ, Barst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nichols J, Hunter C, Sachdev V, Castro O, Gladwin MT: Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 130:445-453, 2005.
20. McMahon CG: Erectile dysfunction. Med J Aust 173:492-497, 2000.
21. McMahon CG: High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 14:533-538, 2002.
22. Meguro T, Chen B, Parent AD, Zhang JH: Caspase inhibitors attenuate oxyhemoglobin-induced apoptosis in endothelial cells. Stroke 32:561-566, 2001.
23. Meguro T, Klett CP, Chen B, Parent AD, Zhang JH: Role of calcium channels in oxyhemoglobin-induced apoptosis in endothelial cells. J Neurosurg 93:640-646, 2000.
24. Nakajima M, Date I, Takahashi K, Ninomiya Y, Asari S, Ohmoto T: Effects of aging on cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke 32:620-628, 2001.
25. Ockaili R, Salloum F, Hawkins J, Kukreja RC: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263-H1269, 2002.
26. Ogihara K, Zubkov AY, Bernanke DH, Lewis AI, Parent AD, Zhang JH: Oxyhemoglobin-induced apoptosis in cultured endothelial cells. J Neurosurg 91:459-465, 1999.
27. Park S, Yamaguchi M, Zhou C, Calvert JW, Tang JW, Zhang JH: Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke 35:2412-2417, 2004.
28. Peterson EW, Leblanc R: A theory of the mechanism of cerebral vasospasm and its reversal, the role of calcium and cyclic AMP. Can J Neurol Sci 3:223-226, 1976.
29. Peterson EW, Searle R, Mandy FF, Leblanc R: The reversal of experimental vasospasm by dibutyryl-3,′ 5′-adenosine monophosphate. J Neurosurg 39:730-734, 1973.
30. Pradilla G, Thai QA, Legnani FG, Hsu W, Kretzer RM, Wang PP, Tamargo RJ: Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. Neurosurgery 55:1393-1400, 2004.
31. Pluta RM: Delayed cerebral vasospasm and nitric oxide: Review, new hypothesis, and proposed treatment. Pharmacol Ther 105:23-56, 2005.
32. Satoh M, Date I, Nakajima M, Takahashi K, Iseda K, Tamiya T, Ohmoto T, Ninomiya Y, Asari S: Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke 32:225-231, 2001.
33. Seftel AD: From aspiration to achievement: Assessment and noninvasive treatment of erectile dysfunction in aging men. J Am Geriatr Soc 53:119-130, 2005.
34. Sobey CG: Cerebrovascular dysfunction after subarachnoid haemorrhage: Novel mechanisms and directions for therapy. Clin Exp Pharmacol Physiol 28:926-929, 2001.
35. Sobey CG, Quan L: Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. Am J Physiol 277:H1718-H1724, 1999.
36. Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH: Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors. J Cereb Blood Flow Metab 17:210-219, 1997.
37. Zhou C, Yamaguchi M, Kusaka G, Schonholz C, Nanda A, Zhang JH: Caspase inhibitors prevent endothelial apoptosis and cerebral vasospasm in dog model of experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 24:419-431,2004.
38. Zubkov AY, Aoki K, Parent AD, Zhang JH: Preliminary study of the effects of caspase inhibitors on vasospasm in dog penetrating arteries. Life Sci 70:3007-3018, 2002.